General Comments / Chat, page-10123

I won’t ask if you are referring to FRE, it’s too soon.

Independent validation on FTO x2, Dominissini silence and adding Oncolines pan-tumour FTO basket.

Cardio protect, no observations of adverse cardiac events in all historical trials mono therapy. Combo therapy Ara-C and Clo Flu were the same even though they are cardiotoxic.

@johndprent whilst possible it doesn’t translate until it is announced no doubt in my mind. Just canvassing the room.

Some risks are combo create adverse effects. But the planned trial is Dox combo and Bisantrene is a modified Dox and same drug class anthracycline.

Dosing might not be optimal to maximise both cardiotoxicity and anti-cancer. Low dose works for anti cancer and cardio protection also increases as dose increases.

Good news is P1 ought to confirm cardio protect, FTO and safety. Efficacy for Metatastic BC in historical trials and other cancers. P2 will valid in modern trial and form some correlation to FTO.

Exciting times, again reiterates are 12 months and counting before P1 underway.